CONTINUE TO SITE

OR WAIT null SECS

Carl Zeiss Case Studies High-Frequency Deep Sclerotomy A MIGS Procedure for Mild-to-Moderate Glaucoma iCare COMPASS Automated Perimeter

Carl Zeiss Case Studies High-Frequency Deep Sclerotomy A MIGS Procedure for Mild-to-Moderate Glaucoma iCare COMPASS Automated Perimeter

View More Cataract & Refractive Cornea Gene Therapy Glaucoma Inflammation & Infection Paediatrics Retina

Cataract & Refractive Cornea Gene Therapy Glaucoma Inflammation & Infection Paediatrics Retina

Medical World News

Eyeviews Medical World News Podcasts Rapid Readouts Viewpoints

Digital Edition

Supplements And Featured Publications

Digital Edition Supplements And Featured Publications

Conference Coverage

Conference Listing

Sponsored Resources

Zeiss Case Studies

Sponsored Resources Zeiss Case Studies

Print Subscription

eNewsletter Print Subscription

Advertise
Editorial Info
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2022 MJH Life Sciences and Opthalmology Times Europe. All rights reserved.

.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

Carl Zeiss Case Studies
High-Frequency Deep Sclerotomy A MIGS Procedure for Mild-to-Moderate Glaucoma
iCare COMPASS Automated Perimeter

ClinicalSee All >

Cataract & Refractive
Cornea
Gene Therapy
Glaucoma
Inflammation & Infection
Paediatrics
Retina

Advertise
Editorial Info
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2022 MJH Life Sciences^™ and Opthalmology Times Europe. All rights reserved.

Marketed AMD therapies

November 28, 2007

Take a look at the therapies that have already reached the market.

Related Content:

Poor post-pandemic follow-up care in glaucoma patients prompts concern

Poor post-pandemic follow-up care in glaucoma patients prompts concern

Genetic testing for keratoconus facilitates earlier recognition of condition

Genetic testing for keratoconus facilitates earlier recognition of condition

Mont Blanc: Final visit completed in Phase 3 trial of NCX 470 for the treatment of glaucoma

Mont Blanc: Final visit completed in Phase 3 trial of NCX 470 for the treatment of glaucoma